表紙
市場調査レポート

harmaPoint:脂質異常症 - 世界の医薬品予測・市場分析

PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2023

発行 GlobalData 商品コード 336855
出版日 ページ情報 英文 438 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.55円で換算しております。
Back to Top
harmaPoint:脂質異常症 - 世界の医薬品予測・市場分析 PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2023
出版日: 2015年05月05日 ページ情報: 英文 438 Pages
概要

世界における脂質異常症 (高脂血症) 治療薬の市場規模は、2013年に154億米ドルとなり、ブランド薬の売上が110億米ドル (72%) 、ジェネリック薬の売り上げが44億米ドル (28%) を構成しました。脂質異常症治療薬市場は予測期間の10年間に9.4%のCAGRで成長すると予測され、市場規模は2023年までに379億米ドルに達すると見込まれ、ブランド薬の売り上げが269億米ドル (71%) 、ジェネリック薬の売り上げが110億米ドル (29%) を構成すると予測されています。

当レポートでは、世界の脂質異常症 (高脂血症) 市場について調査し、脂質異常症の概要、治療薬の年間市場収益・年間コスト・利用パターンに関するデータ・10年間の予測、アンメットニーズ、R&D・臨床試験の評価、パイプライン分析、および現在・将来の競合状況の分析などをまとめています。

第1章 目次

第2章 イントロダクション

第3章 疾病の概要

  • 病因・病態生理学
  • 症状
  • 予後
  • 生活の質

第4章 疫学

  • リスク因子・併存疾患
  • 世界・歴史的な動向
    • 米国
    • EU5カ国
    • アジア
  • 予測手法
    • 利用ソース
    • 予測の前提条件・手法
  • 脂質異常症の罹患率
    • 全体罹患率
    • 年齢別罹患率
    • 性別罹患率
    • 年齢調整罹患率
  • 家族性高コレステロール血症の疫学的予測
    • 全体罹患率
  • 高LDLコレステロール血症の疫学的予測
    • 全体罹患率
    • 年齢別罹患率
    • 性別罹患率
    • 年齢調整罹患率
  • 高TG血症 (500mg/dL以上) の疫学的予測
    • 全体罹患率
    • 年齢別罹患率
    • 性別罹患率
    • 年齢調整罹患率
  • 議論

第5章 疾病管理

  • 診断・治療の概要
    • 治療ガイドライン・主な処方薬
    • 臨床診療
  • 米国
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • 日本
  • 中国

第6章 競合評価

  • 概要
  • 製品プロファイル:主要ブランド
    • スタチン
    • ゼチーア (エゼチミブ)
    • Vytorin (シンバスタチン/エゼチミブ)
    • Liptruzet (アトルバスタチン/エゼチミブ)
    • ナアスパン (ナイアシン徐放性)
    • Kynamro (ミポメルセンナトリウム)
    • Juxtapid (ロミタピド)
    • TriCor/Trilipix (フェノフィブラート/fenfibric acid)
    • オメガ3脂肪酸
    • Welchol (コレセベラム) および the Bile Acid Sequestrants

第7章 アンメットニーズ・機会

  • 概要
  • スタチン不耐性・スタチン不応性患者へのLDC-C降下剤
    • アンメットニーズ
    • ギャップ分析
    • 機会
  • 診断・患者教育・長期的コンプライアンスの向上
  • アテローム性動脈硬化性プラークの防止または蓄積を無効にする治療薬
  • 副作用改善のプロファイルを持つHoFH (ホモ接合型家族性高コレステロール血症) 患者向けの治療

第8章 パイプライン評価

  • 概要
  • 臨床試験マッピング
  • 臨床開発中の有望な薬剤
    • Alirocumab
    • Bococizumab
    • Evolocumab
    • Anacetrapib
    • Evacetrapib
    • TA-8995 (DEZ-001)
    • CER-001
    • ETC-1002
  • その他の開発中の薬剤

第9章 現在・将来の企業

  • 概要
  • 企業戦略における動向
  • 企業プロファイル
    • AbbVie
    • Aegerion Pharmaceuticals, Inc.
    • Amarin
    • Amgen
    • AstraZeneca
    • Cerenis Therapeutics Inc.
    • 第一三共
    • Dezima Pharma
    • Eli Lilly
    • Esperion Therapeutics, Inc.
    • Genzyme
    • GlaxoSmithKline
    • Merck & Co.
    • Pfizer
    • Regeneron Pharmaceuticals, Inc.
    • Sanofi

第10章 市場展望

  • 世界市場
    • 予測
    • 促進因子・阻害因子
  • 米国
  • EU5カ国
  • 日本
  • 中国

第11章 付録

図表

目次
Product Code: GDHC110PIDR

GlobalData estimates that the total market size for the 8MM in 2013 was $15.4bn, comprised of $11.0bn in branded drug sales (72%) and $4.4bn in generic sales (28%). GlobalData expects that the dyslipidemia drug market will grow at a CAGR of 9.4% over the ten year forecast period, resulting in a market value of $37.9bn by 2023, of which 71% will be attributed to branded drug sales ($26.9bn) and 29% to generic drug sales ($11.0bn). The current dyslipidemia market is dominated by the statins, the revolutionary drugs that reduce low-density lipoprotein cholesterol (LDL-C) and that have been proven to reduce the risk of cardiovascular events such as heart attack and stroke. Other major lipid-modulating drugs, such as Zetia (ezetimibe), the fibrates, bile acid sequestrants, omega-3 fish oil agents, and rare-disease therapies comprise the remainder of the current dyslipidemia space. The launch of the proprotein convertase subtilisin/kexin type 9 (PCSK9) biologics and the cholesteryl ester transfer protein (CETP) inhibitors will reshape the sales landscape of the dyslipidemia market moving forward.

Highlights

Key Questions Answered

  • How will major clinical trials of currently marketed therapies impact the future of the dyslipidemia market? Particular attention will be given to the HPS2-THRIVE and IMPROVE-IT Phase III studies of niacin and Zetia (ezetimibe).
  • What role will statins play in the future of the dyslipidemia market?
  • What are the clinical, regulatory, and commercial prospects of the proprotein convertase subtilisin/kexin type 9 monoclonal antibodies (PCSK9 mAbs) from Amgen, Sanofi/Regeneron, and Pfizer and the cholesteryl ester transfer protein (CETP) inhibitors from Eli Lilly, Merck, and Dezima Pharma?
  • How will novel lipid-modulating agents, such as Esperion Therapeutic's ETC-1002 and Cerenis Therapeutic's CER-001, impact the dynamics of the dyslipidemia market?
  • What are the key market drivers, barriers, and unmet needs that remain unaddressed by currently marketed therapies? What will remain unaddressed by the current dyslipidemia pipeline?

Key Findings

  • The highest-impact driver of the dyslipidemia market will be the launch of the PCSK9 inhibitors, human monoclonal antibody biologics that will be used to treat high LDL-C in addition to statins. Therapeutic novelty combined with biologic pricing will make the PCSK9s the largest contributors to dyslipidemia market growth, even if their use is reserved for niche or high-risk cases.
  • The CETP inhibitors in the late-stage pipeline have the potential to bring a novel tool to bear against high LDL-C and low HDL-C. However, their success at the regulatory level will depend heavily on their success in major Phase III cardiovascular outcomes trials, making the CETPs the wild-cards of the dyslipidemia pipeline.
  • Due to the maturity of the current dyslipidemia market, new therapies will need to exploit novel mechanisms of action and/or target orphan drug targets and are more likely to be utilized as add-on therapies to existing treatments. There is a unique opportunity in the familial hypercholesterolemia arena, where effective LDL-C lowering therapies are needed that exhibit clean safety/side-effect profiles.

Scope

  • Overview of dyslipidemia, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized dyslipidemia therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the dyslipidemia therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global dyslipidemia therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the dyslipidemia therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the dyslipidemia therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the 8MM dyslipidemia therapeutics market from 2013-2023.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms
  • 3.3. Prognosis
  • 3.4. Quality of Life

4. Epidemiology

  • 4.1. Risk Factors and Comorbidities
  • 4.2. Global and Historical Trends
    • 4.2.1. US
    • 4.2.2. 5EU
    • 4.2.3. Asia
  • 4.3. Forecast Methodology
    • 4.3.1. Sources Used
    • 4.3.2. Forecast Assumptions and Methods
    • 4.3.3. Sources Not Used
  • 4.4. Prevalent Cases of Dyslipidemia
    • 4.4.1. Total Prevalent Cases of Dyslipidemia
    • 4.4.2. Age-Specific Total Prevalent Cases of Dyslipidemia
    • 4.4.3. Sex-Specific Total Prevalent Cases of Dyslipidemia
    • 4.4.4. Age-Standardized Total Prevalence of Dyslipidemia
  • 4.5. Epidemiological Forecast for Familial Hypercholesterolemia (2013-2023)
    • 4.5.1. Total Prevalent Cases of Familial Hypercholesterolemia
  • 4.6. Epidemiological Forecast for Increased LDL-C (2013-2023)
    • 4.6.1. Total Prevalent Cases of Increased LDL-C
    • 4.6.2. Age-Specific Total Prevalent Cases of Increased LDL-C
    • 4.6.3. Sex-Specific Total Prevalent Cases of Increased LDL-C
    • 4.6.4. Age-Standardized Total Prevalence of Increased LDL-C
  • 4.7. Epidemiological Forecast for Very High TG (≥500mg/dL) (2013-2023)
    • 4.7.1. Total Prevalent Cases of Very High TG (≥500mg/dL)
    • 4.7.2. Age-Specific Total Prevalent Cases of Very High TG (≥500mg/dL)
    • 4.7.3. Sex-Specific Total Prevalent Cases of Very High TG (≥500mg/dL)
    • 4.7.4. Age-Standardized Total Prevalence of Very High TG (≥500mg/dL)
  • 4.8. Discussion
    • 4.8.1. Epidemiological Forecast Insight
    • 4.8.2. Limitations of the Analysis
    • 4.8.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Diagnosis and Treatment Overview
    • 5.1.1. Diagnosis
    • 5.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 5.1.3. Clinical Practice
  • 5.2. US
  • 5.3. France
  • 5.4. Germany
  • 5.5. Italy
  • 5.6. Spain
  • 5.7. UK
  • 5.8. Japan
  • 5.9. China

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Product Profiles - Major Brands
    • 6.2.1. Statins
    • 6.2.2. Zetia (ezetimibe)
    • 6.2.3. Vytorin (simvastatin/ezetimibe)
    • 6.2.4. Liptruzet (atorvastatin/ezetimibe)
    • 6.2.5. Niaspan (niacin extended-release)
    • 6.2.6. Kynamro (mipomersen sodium)
    • 6.2.7. Juxtapid (lomitapide)
    • 6.2.8. TriCor/Trilipix (fenofibrate/fenfibric acid)
    • 6.2.9. Omega-3 Fatty Acids
    • 6.2.10. Welchol (colesevelam HCl) and the Bile Acid Sequestrants

7. Unmet Need and Opportunity

  • 7.1. Overview
  • 7.2. LDL-C-Lowering Drugs for Statin-Intolerant and Statin-Refractory Patients
    • 7.2.1. Unmet Need
    • 7.2.2. Gap Analysis
    • 7.2.3. Opportunity
  • 7.3. Improved Diagnosis, Patient Education, and Long-term Compliance
    • 7.3.1. Unmet Need
    • 7.3.2. Gap Analysis
    • 7.3.3. Opportunity
  • 7.4. Therapies that Prevent or Reverse the Build-Up of Atherosclerotic Plaque
    • 7.4.1. Unmet Need
    • 7.4.2. Gap Analysis
    • 7.4.3. Opportunity
  • 7.5. Therapies for Patients with HoFH with Improved Side Effect Profiles
    • 7.5.1. Unmet Need
    • 7.5.2. Gap Analysis
    • 7.5.3. Opportunity

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Clinical Trial Mapping
    • 8.2.1. Clinical Trials by Patient Population
  • 8.3. Promising Drugs in Clinical Development
    • 8.3.1. Alirocumab
    • 8.3.2. Bococizumab
    • 8.3.3. Evolocumab
    • 8.3.4. Anacetrapib
    • 8.3.5. Evacetrapib
    • 8.3.6. TA-8995 (DEZ-001)
    • 8.3.7. CER-001
    • 8.3.8. ETC-1002
  • 8.4. Other Drugs in Development

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. AbbVie
    • 9.3.2. Aegerion Pharmaceuticals, Inc.
    • 9.3.3. Amarin
    • 9.3.4. Amgen
    • 9.3.5. AstraZeneca
    • 9.3.6. Cerenis Therapeutics Inc.
    • 9.3.7. Daiichi Sankyo
    • 9.3.8. Dezima Pharma
    • 9.3.9. Eli Lilly
    • 9.3.10. Esperion Therapeutics, Inc.
    • 9.3.11. Genzyme
    • 9.3.12. GlaxoSmithKline
    • 9.3.13. Merck & Co.
    • 9.3.14. Pfizer
    • 9.3.15. Regeneron Pharmaceuticals, Inc.
    • 9.3.16. Sanofi

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers - Global Issues
  • 10.2. United States
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. 5EU
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers
  • 10.4. Japan
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers
  • 10.5. China
    • 10.5.1. Forecast
    • 10.5.2. Key Events
    • 10.5.3. Drivers and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Diagnosed Dyslipidemia Patients
    • 11.4.2. Percent Drug-Treated Patients
    • 11.4.3. Drugs Included in Each Therapeutic Class
    • 11.4.4. Launch and Patent Expiry Dates
    • 11.4.5. General Pricing Assumptions
    • 11.4.6. Individual Drug Assumptions
    • 11.4.7. Generic Erosion
    • 11.4.8. Pricing of Pipeline Agents
  • 11.5. Physicians and Specialists Included in this Study
  • 11.6. About the Authors
    • 11.6.1. Analyst
    • 11.6.2. Therapy Area Director
    • 11.6.3. Epidemiologist
    • 11.6.4. Global Head of Healthcare
  • 11.7. About GlobalData
  • 11.8. Disclaimer

List of Tables

  • Table 1: Dyslipidemia: Key Metrics in Eight Major Pharmaceutical Markets
  • Table 2: Common Secondary Causes of Dyslipidemia
  • Table 3: Risk Factors and Comorbidities for Dyslipidemia
  • Table 4: Overview of the Total Prevalence of Low HDL-C in the 5EU
  • Table 5: NCEP ATP III Classification of LDL-C, TG, and HDL-C
  • Table 6: Simon Broome Diagnostic Criteria for FH
  • Table 7: LDL-C Based Definition of FH
  • Table 8: Sources of Total Prevalence Data for FH in the 8MM
  • Table 9: Sources of Total Prevalence Data for Increased LDL-C in the 8MM
  • Table 10: Sources of Total Prevalence Data for High TG (≥200mg/dL) in the 8MM
  • Table 11: Sources of Total Prevalence Data for Very High TG (≥500mg/dL) in the 8MM
  • Table 12: Sources of Total Prevalence Data for Low HDL-C in the 8MM
  • Table 13: 8MM, Sources Not Used in the Epidemiological Analysis of Dyslipidemia
  • Table 14: 8MM, Total Prevalent Cases of Dyslipidemia, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Table 15: 8MM, Age-Specific Total Prevalent Cases of Dyslipidemia, Both Sexes, N (Row %), 2013
  • Table 16: 8MM, Sex-Specific Total Prevalent Cases of Dyslipidemia, Ages ≥20 Years, N (Row %), 2013
  • Table 17: 8MM, Total Prevalent Cases of Familial Hypercholesterolemia, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Table 18: 8MM, Total Prevalent Cases of Increased LDL-C* (≥115mg/dL to ≥160mg/dL), Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Table 19: 8MM, Age-Specific Total Prevalent Cases of Increased LDL-C* (≥115mg/dL to ≥160mg/dL), Both Sexes, N (Row %), 2013
  • Table 20: 8MM, Sex-Specific Total Prevalent Cases of Increased LDL-C* (≥115mg/dL to ≥160mg/dL), Ages ≥20 Years, N (Row %), 2013
  • Table 21: 8MM, Total Prevalent Cases of Very High TG (≥500mg/dL), Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Table 22: 8MM, Age-Specific Total Prevalent Cases of Very High TG (≥500mg/dL), Both Sexes, N (Row %), 2013
  • Table 23: 8MM, Sex-Specific Total Prevalent Cases of Very High TG (≥500mg/dL), Ages ≥20 Years, N (Row %), 2013
  • Table 24: Treatment Guidelines for Dyslipidemia
  • Table 25: Most Commonly Prescribed Drugs for Dyslipidemia by Class in the Global Markets, 2014
  • Table 26: Country Profile - US
  • Table 27: Country Profile - France
  • Table 28: Country Profile - Germany
  • Table 29: Country Profile - Italy
  • Table 30: Country Profile - Spain
  • Table 31: Country Profile - UK
  • Table 32: Country Profile - Japan
  • Table 33: Country Profile - China
  • Table 34: Leading Treatments for Dyslipidemia, 2014
  • Table 35: Statin Combination Therapies
  • Table 36: Product Profile - Lipitor
  • Table 37: Lipitor (atorvastatin) SWOT Analysis, 2014
  • Table 38: Global Sales Forecasts ($m) for Lipitor (atorvastatin), 2013-2023
  • Table 39: Product Profile - Crestor (rosuvastatin)
  • Table 40: Crestor (rosuvastatin) SWOT Analysis, 2014
  • Table 41: Global Sales Forecasts ($m) for Crestor (rosuvastatin), 2013-2023
  • Table 42: Product Profile - Zocor (simvastatin)
  • Table 43: Zocor (simvastatin) SWOT Analysis, 2014
  • Table 44: Global Sales Forecasts ($m) for Zocor (simvastatin), 2013-2023
  • Table 45: Product Profile - Livalo (pitavastatin)
  • Table 46: Livalo (pitavastatin) SWOT Analysis, 2014
  • Table 47: Product Profile - Zetia (ezetimibe)
  • Table 48: Zetia (ezetimibe) SWOT Analysis, 2014
  • Table 49: Global Sales Forecasts ($m) for Zetia (ezetimibe), 2013-2023
  • Table 50: Product Profile - Vytorin (simvastatin/ezetimibe)
  • Table 51: Vytorin (simvastatin/ezetimibe) SWOT Analysis, 2014
  • Table 52: Global Sales Forecasts ($m) for Vytorin (simvastatin/ezetimibe), 2013-2023
  • Table 53: Product Profile - Liptruzet (atorvastatin/ezetimibe)
  • Table 54: Liptruzet (atorvastatin/ezetimibe) SWOT Analysis, 2014
  • Table 55: Global Sales Forecasts ($m) for Liptruzet (atorvastatin/ezetimibe), 2013-2023
  • Table 56: Product Profile - Niaspan (niacin extended-release)
  • Table 57: Niaspan (niacin extended-release) SWOT Analysis, 2014
  • Table 58: Global Sales Forecasts ($m) for Niaspan (niacin extended-release), 2013-2023
  • Table 59: Product Profile - Kynamro (mipomersen sodium)
  • Table 60: Kynamro-Induced Changes in Lipid Parameters from Akdim et al., 2010
  • Table 61: Kynamro-Induced Changes in Lipid Parameters from Raal et al., 2010
  • Table 62: Kynamro (mipomersen) SWOT Analysis, 2014
  • Table 63: Global Sales Forecasts ($m) for Kynamro (mipomersen), 2013-2023
  • Table 64: Product Profile - Juxtapid (lomitapide)
  • Table 65: Juxtapid-Induced Dose-Responsive Changes in Lipid Parameters from Cuchel et al., 2007
  • Table 66: Juxtapid-Induced Changes in Lipid Parameters from Cuchel et al., 2013
  • Table 67: Juxtapid (lomitapide) SWOT Analysis, 2014
  • Table 68: Global Sales Forecasts ($m) for Juxtapid (lomitapide), 2013-2023
  • Table 69: A Summary of the Therapeutic Properties of Fibrates*
  • Table 70: Product Profile - TriCor (fenofibrate) and Trilipix (fenofibric acid)
  • Table 71: TriCor/Trilipix (fenofibrate/fenofibric acid) SWOT Analysis, 2014
  • Table 72: Global Sales Forecasts ($m) for TriCor/Trilipix (fenofibrate/fenofibric acid), 2013-2023
  • Table 73: Product Profile - Lovaza (omega-3 acid ethyl esters)
  • Table 74: Lovaza (omega-3 acid ethyl esters) SWOT Analysis, 2014
  • Table 75: Global Sales Forecasts ($m) for Lovaza (omega-3 acid ethyl esters), 2013-2023
  • Table 76: Product Profile - Vascepa (icosapent ethyl)
  • Table 77: Vascepa (icosapent ethyl) SWOT Analysis, 2014
  • Table 78: Global Sales Forecasts ($m) for Vascepa (icosapent ethyl), 2013-2023
  • Table 79: Product Profile - Epanova (omega-3 carboxylic acids)
  • Table 80: Epanova-Induced Changes in Blood Lipid Parameters from Kastelein et al., 2012
  • Table 81: Epanova-Induced Changes in Blood Lipid Parameters from Maki et al., 2013
  • Table 82: Epanova (omega-3 carboxylic acids) SWOT Analysis, 2014
  • Table 83: Global Sales Forecasts ($m) for Epanova (omega-3 carboxylic acids), 2013-2023
  • Table 84: Product Profile - Welchol (colesevelam HCl)
  • Table 85: Welchol-Induced Changes in Blood Glucose and Lipid Parameters from Zieve et al., 2007
  • Table 86: Welchol (colesevelam HCl) SWOT Analysis, 2014
  • Table 87: Global Sales Forecasts ($m) for Welchol (colesevelam HCl), 2013-2023
  • Table 88: Unmet Need and Opportunity in Dyslipidemia
  • Table 89: Comparison of Therapeutic Classes in Development for Dyslipidemia, 2014
  • Table 90: Product Profile - Alirocumab
  • Table 91: Alirocumab SWOT Analysis, 2014
  • Table 92: Global Sales Forecasts ($m) for Alirocumab, 2013-2023
  • Table 93: Product Profile - Bococizumab
  • Table 94: Bococizumab SWOT Analysis, 2014
  • Table 95: Global Sales Forecasts ($m) for Bococizumab, 2013-2023
  • Table 96: Product Profile - Evolocumab
  • Table 97: Phase III Clinical Trials of Evolocumab Reported by Amgen from Q4 2013 - Q1 2014
  • Table 98: Evolocumab SWOT Analysis, 2014
  • Table 99: Global Sales Forecasts ($) for Evolocumab, 2013-2023
  • Table 100: Product Profile - Anacetrapib
  • Table 101: Anacetrapib SWOT Analysis, 2014
  • Table 102: Global Sales Forecasts ($) for Anacetrapib, 2013-2023
  • Table 103: Product Profile - Evacetrapib
  • Table 104: Evacetrapib SWOT Analysis, 2014
  • Table 105: Global Sales Forecasts ($) for Evacetrapib, 2013-2023
  • Table 106: Product Profile - TA-8995 (DEZ-001)
  • Table 107: Impact of Steady-State TA-8995 on CETP and Lipid Parameters from Ford et al., 2014
  • Table 108: TA-8995 SWOT Analysis, 2014
  • Table 109: Global Sales Forecasts ($) for TA-8995, 2013-2023
  • Table 110: Product Profile - CER-001
  • Table 111: CER-001 SWOT Analysis, 2014
  • Table 112: Global Sales Forecasts ($) for CER-001, 2013-2023
  • Table 113: Product Profile - ETC-1002
  • Table 114: ETC-1002/Ezetimibe Active Comparator Trial Results
  • Table 115: ETC-1002 SWOT Analysis, 2014
  • Table 116: Global Sales Forecasts ($) for ETC-1002, 2013-2023
  • Table 117: Dyslipidemia Drugs in Development, 2014
  • Table 118: Key Companies in the Dyslipidemia Market in the 8MM, 2014
  • Table 119: AbbVie's Dyslipidemia Portfolio Assessment, 2014
  • Table 120: Aegerion's Dyslipidemia Portfolio Assessment, 2014
  • Table 121: Amarin's Dyslipidemia Portfolio Assessment, 2014
  • Table 122: Amgen's Dyslipidemia Portfolio Assessment, 2014
  • Table 123: AstraZeneca's Dyslipidemia Portfolio Assessment, 2014
  • Table 124: Cerenis' Dyslipidemia Portfolio Assessment, 2014
  • Table 125: Daiichi Sankyo's Dyslipidemia Portfolio Assessment, 2014
  • Table 126: Dezima's Dyslipidemia Portfolio Assessment, 2014
  • Table 127: Eli Lilly's Dyslipidemia Portfolio Assessment, 2014
  • Table 128: Esperion's Dyslipidemia Portfolio Assessment, 2014
  • Table 129: Genzyme's Dyslipidemia Portfolio Assessment, 2014
  • Table 130: GlaxoSmithKline's Dyslipidemia Portfolio Assessment, 2014
  • Table 131: Merck's Dyslipidemia Portfolio Assessment, 2014
  • Table 132: Pfizer's Dyslipidemia Portfolio Assessment, 2014
  • Table 133: Regeneron's Dyslipidemia Portfolio Assessment, 2014
  • Table 134: Sanofi's Dyslipidemia Portfolio Assessment, 2014
  • Table 135: Global Sales Forecasts ($m) for Dyslipidemia, 2013-2023
  • Table 136: Dyslipidemia Market - Drivers and Barriers, 2014
  • Table 137: Sales Forecasts ($) for Dyslipidemia in the United States, 2013-2023
  • Table 138: Key Events Impacting Sales for Dyslipidemia in the US, 2014
  • Table 139: Dyslipidemia Market - US Drivers and Barriers, 2014
  • Table 140: Sales Forecast ($m) for Dyslipidemia in the 5EU, 2013-2023
  • Table 141: Key Events Impacting Sales for Dyslipidemia in the 5EU, 2014
  • Table 142: Dyslipidemia Market - 5EU Drivers and Barriers, 2014
  • Table 143: National Healthcare Authorities in the 5EU Nations
  • Table 144: National Public Health Initiatives in the 5EU Nations
  • Table 145: Governmental Drug Pricing Authorities in the 5EU Nations
  • Table 146: Sales Forecasts ($) for Dyslipidemia in Japan, 2013-2023
  • Table 147: Key Events Impacting Sales for Dyslipidemia in Japan, 2014
  • Table 148: Dyslipidemia Market - Japan Drivers and Barriers, 2014
  • Table 149: Sales Forecasts ($) for Dyslipidemia in China, 2013-2023
  • Table 150: Key Events Impacting Sales for Dyslipidemia in China, 2014
  • Table 151: Dyslipidemia Market - China Drivers and Barriers, 2014
  • Table 152: Key Launch Dates
  • Table 153: Key Patent Expiries
  • Table 154: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country

List of Figures

  • Figure 1: 8MM, Total Prevalent Cases of Dyslipidemia, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Figure 2: 8MM, Age-Specific Total Prevalent Cases of Dyslipidemia, Both Sexes, Ages ≥20 Years, N, 2013
  • Figure 3: 8MM, Sex-Specific Total Prevalent Cases of Dyslipidemia, Ages ≥20 Years, N, 2013
  • Figure 4: 8MM, Age-Standardized Total Prevalence of Dyslipidemia (%), Ages ≥20 Years, by Sex, 2013
  • Figure 5: 8MM, Total Prevalent Cases of Familial Hypercholesterolemia, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Figure 6: 8MM, Total Prevalent Cases of Increased LDL-C* (≥115mg/dL to ≥160mg/dL), Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Figure 7: 8MM, Age-Specific Total Prevalent Cases of Increased LDL-C* (≥115mg/dL to ≥160mg/dL), Both Sexes, Ages ≥20 Years, N, 2013
  • Figure 8: 8MM, Sex-Specific Total Prevalent Cases of Increased LDL-C* (≥115mg/dL to ≥160mg/dL), Ages ≥20 Years, N, 2013
  • Figure 9: 8MM, Age-Standardized Total Prevalence of Increased LDL-C (≥115mg/dL to ≥160mg/dL)* (%), Ages ≥20 Years, by Sex, 2013
  • Figure 10: 8MM, Total Prevalent Cases of Very High TG (≥500mg/dL), Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Figure 11: 8MM, Age-Specific Total Prevalent Cases of Very High TG (≥500mg/dL), Both Sexes, Ages ≥20 Years, N, 2013
  • Figure 12: 8MM, Sex-Specific Total Prevalent Cases of Very High TG (≥500mg/dL), Ages ≥20 Years, N, 2013
  • Figure 13: 8MM, Age-Standardized Total Prevalence of Very High TG (≥500mg/dL) (%), Ages ≥20 Years, by Sex, 2013
  • Figure 14: Competitive Assessment of Late-Stage Pipeline Agents in Dyslipidemia, 2013-2023
  • Figure 15: Dyslipidemia Therapeutics - Clinical Trials by Indication and Lipid Biomarker, 2014
  • Figure 16: Global Sales of Branded Products for Dyslipidemia by Company, 2013-2023
  • Figure 17: Company Portfolio Gap Analysis in Dyslipidemia, 2013-2023
  • Figure 18: Global Sales for Dyslipidemia by Country, 2013-2023
  • Figure 19: Global Sales for Dyslipidemia by Drug Class, 2013-2023
  • Figure 20: Global Sales Forecast for PCSK9 mAbs, 2015-2023
  • Figure 21: Projected Global Sales of Dyslipidemia Drugs by Year, 2013-2023
  • Figure 22: Sales for Dyslipidemia in the United States by Drug Class, 2013-2023
  • Figure 23: Composite Sales for Dyslipidemia in the 5EU by Drug Class, 2013-2023
  • Figure 24: Sales Breakdown for the 5EU Markets, 2013-2023
  • Figure 25: 5EU Country Sales, Segmented by Drug Class, 2013-2023
  • Figure 26: High-Selling* Drug Classes in the 5EU, Segmented by Country, 2013-2023
  • Figure 27: Low-Selling* Drug Classes in the 5EU, Segmented by Country, 2013-2023
  • Figure 28: Sales for Dyslipidemia in Japan by Drug Class, 2013-2023
  • Figure 29: Sales for Dyslipidemia in China by Drug Class, 2013-2023
Back to Top